Scenesse® Approved in Australia!

Friday, October 30, 2020

CLINUVEL PHARMACEUTICALS LTD announced this week that the Australian Therapeutic Goods Administration (TGA) has approved the registration of its drug SCENESSE® (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). SCENESSE® is the first treatment approved for EPP patients in Australia.

Click Here to Read the Full Press Release